当前位置:
X-MOL 学术
›
Lancet Respir. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Where are the innovations in tuberculosis drug discovery?
The Lancet Respiratory Medicine ( IF 38.7 ) Pub Date : 2017-10-04 , DOI: 10.1016/s2213-2600(17)30376-4 The Lancet Respiratory Medicine
The Lancet Respiratory Medicine ( IF 38.7 ) Pub Date : 2017-10-04 , DOI: 10.1016/s2213-2600(17)30376-4 The Lancet Respiratory Medicine
WHO has released a report that highlights a serious lack of antibiotics in clinical development; a worrying finding in an era of antimicrobial resistance. The report identifies a particular shortage of antibiotics under development for multidrug-resistant tuberculosis, which is a disease that kills a quarter of a million people every year.
中文翻译:
结核病药物发现的创新在哪里?
世卫组织发布了一份报告,强调在临床开发中严重缺乏抗生素。在抗菌素耐药性时代令人担忧的发现。该报告指出,正在为耐多药结核病开发的抗生素特别短缺,这种疾病每年夺去四分之一的人的生命。
更新日期:2017-11-10
中文翻译:
结核病药物发现的创新在哪里?
世卫组织发布了一份报告,强调在临床开发中严重缺乏抗生素。在抗菌素耐药性时代令人担忧的发现。该报告指出,正在为耐多药结核病开发的抗生素特别短缺,这种疾病每年夺去四分之一的人的生命。